

Cell Surface Marker for Detection of Activated B Cells involved in Disease

Tech ID: 23028 / UC Case 2012-349-0

BACKGROUND

Proteins expressed in the membrane of B cells represent compelling targets for therapeutic monoclonal antibody development. Although drugs are commercially available, for example, Rituxan®, which targets CD20, a cell surface protein present in all B cells, there is currently no therapy that selectively acts on activated B lymphocytes.

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Published Application	20160237152	08/08/2016	2012-349

TECHNOLOGY DESCRIPTION

Researchers at the University of California, Irvine, have discovered a novel marker expressed in activated B cells that can be selectively targeted, for example, using monoclonal antibody therapy.

APPLICATIONS

The present invention provides a novel strategy for selectively targeting or detecting activated B cells in the presence of normal B cells without harming the latter. This innovative research can be exploited in detecting and treating human diseases where activated B cells are involved, e.g., leukemia, autoimmune disease (i.e., lupus, rheumatoid arthritis, etc...), etc...

CONTACT

Ronnie Hanecak
rhanecak@uci.edu
tel: 949-824-7186.



OTHER INFORMATION

KEYWORDS

Marker, Biomarker, activated B cells, leukemia, autoimmune disease, Antibodies

CATEGORIZED AS

- » Medical
 - » Diagnostics
 - » Research Tools
- » Research Tools
 - » Antibodies

RELATED CASES

2012-349-0

UCI Beall
Applied Innovation

5270 California Avenue / Irvine, CA
92697-7700 / Tel: 949.824.2683



© 2013 - 2016, The Regents of the University of
California
[Terms of use](#)
[Privacy Notice](#)